Australia markets closed

Exopharm Limited (EX1.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.01100.0000 (0.00%)
At close: 10:10AM AEST
Currency in AUD

Valuation measures4

Market cap (intra-day) 4.83M
Enterprise value 4.72M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.50
Price/book (mrq)1.17
Enterprise value/revenue 7.64
Enterprise value/EBITDA -7.54

Trading information

Stock price history

Beta (5Y monthly) 1.25
52-week change 344.74%
S&P500 52-week change 325.01%
52-week high 30.0275
52-week low 30.0080
50-day moving average 30.0159
200-day moving average 30.0119

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5175.77M
Implied shares outstanding 6175.77M
Float 8127.58M
% held by insiders 138.21%
% held by institutions 10.00%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:2.5
Last split date 315 Apr 2024

Financial highlights

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-4,420.46%

Management effectiveness

Return on assets (ttm)-51.37%
Return on equity (ttm)-121.54%

Income statement

Revenue (ttm)1.18M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-98.40%
Gross profit (ttm)N/A
EBITDA -2.97M
Net income avi to common (ttm)-4.32M
Diluted EPS (ttm)-0.0900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.61M
Total cash per share (mrq)0.01
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)7.82
Book value per share (mrq)0.01

Cash flow statement

Operating cash flow (ttm)-1.3M
Levered free cash flow (ttm)923.23k